MICROSATELLITE STABLE RECURRENT OR PERSISTENT ENDOMETRIAL CANCER

Clinical trials for MICROSATELLITE STABLE RECURRENT OR PERSISTENT ENDOMETRIAL CANCER explained in plain language.

Never miss a new study

Get alerted when new MICROSATELLITE STABLE RECURRENT OR PERSISTENT ENDOMETRIAL CANCER trials appear

Sign up with your email to follow new studies for MICROSATELLITE STABLE RECURRENT OR PERSISTENT ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug duo shows promise against tough uterine cancer

Disease control Ongoing

This study tested a combination of two drugs, mirvetuximab soravtansine and pembrolizumab, in 18 people with a specific type of advanced or returning endometrial cancer that is microsatellite stable (MSS). The goal was to see if the combo could shrink tumors or stop them from gro…

Matched conditions: MICROSATELLITE STABLE RECURRENT OR PERSISTENT ENDOMETRIAL CANCER

Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control

Last updated Jun 16, 2026 12:51 UTC

MICROSATELLITE STABLE RECURRENT OR PERSISTENT ENDOMETRIAL CANCER

Get alerted when new MICROSATELLITE STABLE RECURRENT OR PERSISTENT ENDOMETRIAL CANCER trials appear

New drug duo shows promise against tough uterine cancer